» Articles » PMID: 30208623

Protein Tyrosine Phosphatases As Potential Regulators of STAT3 Signaling

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2018 Sep 14
PMID 30208623
Citations 83
Authors
Affiliations
Soon will be listed here.
Abstract

The signal transducer and activator of transcription 3 (STAT3) protein is a major transcription factor involved in many cellular processes, such as cell growth and proliferation, differentiation, migration, and cell death or cell apoptosis. It is activated in response to a variety of extracellular stimuli including cytokines and growth factors. The aberrant activation of STAT3 contributes to several human diseases, particularly cancer. Consequently, STAT3-mediated signaling continues to be extensively studied in order to identify potential targets for the development of new and more effective clinical therapeutics. STAT3 activation can be regulated, either positively or negatively, by different posttranslational mechanisms including serine or tyrosine phosphorylation/dephosphorylation, acetylation, or demethylation. One of the major mechanisms that negatively regulates STAT3 activation is dephosphorylation of the tyrosine residue essential for its activation by protein tyrosine phosphatases (PTPs). There are seven PTPs that have been shown to dephosphorylate STAT3 and, thereby, regulate STAT3 signaling: PTP receptor-type D (PTPRD), PTP receptor-type T (PTPRT), PTP receptor-type K (PTPRK), Src homology region 2 (SH-2) domain-containing phosphatase 1(SHP1), SH-2 domain-containing phosphatase 2 (SHP2), MEG2/PTP non-receptor type 9 (PTPN9), and T-cell PTP (TC-PTP)/PTP non-receptor type 2 (PTPN2). These regulators have great potential as targets for the development of more effective therapies against human disease, including cancer.

Citing Articles

Review on role of honey in disease prevention and treatment through modulation of biological activities.

Rahmani A, Babiker A Open Life Sci. 2025; 20(1):20251069.

PMID: 40059876 PMC: 11889511. DOI: 10.1515/biol-2025-1069.


Blockade of the STAT3/BCL-xL Axis Leads to the Cytotoxic and Cisplatin-Sensitizing Effects of Fucoxanthin, a Marine-Derived Carotenoid, on Human Bladder Urothelial Carcinoma Cells.

Dai W, Chen T, Peng T, He Y, Hsu C, Chang C Mar Drugs. 2025; 23(2).

PMID: 39997178 PMC: 11857094. DOI: 10.3390/md23020054.


Chronic Stress Mediates Inflammatory Cytokines Alterations and Its Role in Tumorigenesis.

Liu Z, Lei M, Bai Y J Inflamm Res. 2025; 18:1067-1090.

PMID: 39871957 PMC: 11769853. DOI: 10.2147/JIR.S485159.


Cross-species analysis of genetic architecture and polygenic risk scores for non-contact ACL rupture in dogs and humans.

Momen M, Kearney H, Patterson M, Sample S, Zhao Z, Lu Q Commun Biol. 2025; 8(1):26.

PMID: 39789146 PMC: 11718046. DOI: 10.1038/s42003-024-07395-9.


Advances in peripheral T cell lymphomas: pathogenesis, genetic landscapes and emerging therapeutic targets.

Pichler A, Amador C, Fujimoto A, Takeuchi K, de Jong D, Iqbal J Histopathology. 2024; 86(1):119-133.

PMID: 39679758 PMC: 11648357. DOI: 10.1111/his.15376.


References
1.
Ahn K, Sethi G, Sung B, Goel A, Ralhan R, Aggarwal B . Guggulsterone, a farnesoid X receptor antagonist, inhibits constitutive and inducible STAT3 activation through induction of a protein tyrosine phosphatase SHP-1. Cancer Res. 2008; 68(11):4406-15. DOI: 10.1158/0008-5472.CAN-07-6696. View

2.
Neel B, Gu H, Pao L . The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem Sci. 2003; 28(6):284-93. DOI: 10.1016/S0968-0004(03)00091-4. View

3.
Leibowitz M, Srivastava R, Andrade Filho P, Egloff A, Wang L, Seethala R . SHP2 is overexpressed and inhibits pSTAT1-mediated APM component expression, T-cell attracting chemokine secretion, and CTL recognition in head and neck cancer cells. Clin Cancer Res. 2013; 19(4):798-808. PMC: 3578140. DOI: 10.1158/1078-0432.CCR-12-1517. View

4.
Kim D, Chan K, Sano S, DiGiovanni J . Signal transducer and activator of transcription 3 (Stat3) in epithelial carcinogenesis. Mol Carcinog. 2007; 46(8):725-31. DOI: 10.1002/mc.20342. View

5.
Chim C, Fung T, Cheung W, Liang R, Kwong Y . SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway. Blood. 2004; 103(12):4630-5. DOI: 10.1182/blood-2003-06-2007. View